Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
Division of General Internal Medicine and Health Services Research, School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Addiction. 2024 Dec;119(12):2211-2215. doi: 10.1111/add.16652. Epub 2024 Aug 16.
Extended release buprenorphine injection (INJ-BUP) has been available in the United States since 2018. INJ-BUP has the potential to positively impact opioid use disorder (OUD) treatment outcomes by providing additional treatment options. As one of the largest payers of OUD treatment in the US, Medicaid coverage is important for access and uptake of INJ-BUP. Uptake of INJ-BUP among Medicaid beneficiaries has not been described since 2019 and variation in uptake by state has not previously been explored. We aimed to measure prescribing of INJ-BUP for Medicaid beneficiaries since 2018, nationwide and by state.
We analyzed State Drug Utilization Data from 2017 to 2022 and calculated the number of prescription fills for INJ-BUP and oral buprenorphine paid by Medicaid. To compare across states, we calculated the number of prescription fills per 100 Medicaid beneficiaries treated for OUD using data from Transformed Medicaid Statistical Information System Substance Use Disorder (T-MSIS SUD) Data Books. Data sources are publicly available.
The number of prescription fills for INJ-BUP paid by Medicaid increased from 4322 (0.1% of all buprenorphine prescription fills) in 2018 to 186 861 (2.0%) in 2022. Each year the increase in fills exceeded the prior year change, indicating accelerating uptake. There was notable variability across states.
The number of extended release buprenorphine injection prescriptions among US Medicaid beneficiaries treated for opioid use disorder increased from over 4000 prescriptions in 2018 to over 185 000 in 2022 but uptake is much less than observed in other countries over shorter time periods.
自 2018 年以来，美国已可提供丁丙诺啡延长释放注射剂（INJ-BUP）。通过提供更多的治疗选择，INJ-BUP 有可能对阿片类药物使用障碍（OUD）的治疗结果产生积极影响。作为美国最大的 OUD 治疗支付方之一，医疗补助计划的覆盖范围对于 INJ-BUP 的获得和采用非常重要。自 2019 年以来，尚未有关于医疗补助计划受益者采用 INJ-BUP 的描述，而且各州之间的采用情况也尚未进行过探讨。我们旨在衡量自 2018 年以来全国和各州医疗补助计划受益者使用 INJ-BUP 的处方情况。
我们分析了 2017 年至 2022 年的州药物利用数据，并计算了医疗补助计划支付的 INJ-BUP 和口服丁丙诺啡的处方数量。为了进行各州之间的比较，我们使用 Transformed Medicaid Statistical Information System Substance Use Disorder (T-MSIS SUD) Data Books 中的数据，计算了每 100 名接受 OUD 治疗的 Medicaid 受益者的处方数量。数据来源公开可用。
医疗补助计划支付的 INJ-BUP 处方数量从 2018 年的 4322 张（丁丙诺啡总处方量的 0.1%）增加到 2022 年的 186861 张（2.0%）。每年的处方数量增长都超过了前一年的变化，表明采用速度加快。各州之间存在显著差异。
接受阿片类药物使用障碍治疗的美国医疗补助计划受益者中，丁丙诺啡延长释放注射剂的处方数量从 2018 年的 4000 多张增加到 2022 年的 185000 多张，但与其他国家在较短时间内的采用情况相比，采用率要低得多。
